Physician profile
Shishir Mathur
NPI 1003016957
$11,978.02
in general payments reported to CMS, 2019-2025
42 companies · $4,351 in 2025
The $4,351 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,204 · 2020: $805 · 2021: $332 · 2022: $751 · 2023: $1,238 · 2024: $1,296 · 2025: $4,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,804 · Travel and Lodging: $1,033 · Education: $47.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,804.18 |
| Travel and Lodging | $1,033.28 |
| Education | $47.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,510.33 | 2019-2025 | Xience Skypoint, Jot Dx, Optis |
| Philips North America LLC | $1,880.35 | 2019 | |
| Boston Scientific Corporation | $866.19 | 2021-2025 | Watchman Flx, Watchman Access System, Watchman |
| Amgen INC. | $728.20 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $553.51 | 2019-2020 | |
| Pfizer INC. | $550.03 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $495.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $487.19 | 2019-2025 | Camzyos, Eliquis |
| Shockwave Medical, INC | $469.66 | 2025 | |
| Novo Nordisk INC | $264.19 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $226.91 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $223.98 | 2019-2025 | Farxiga, Wainua |
| Bridgebio Pharma, INC. | $223.91 | 2025 | Attruby |
| Atricure, INC. | $217.55 | 2020-2025 | Atriclip Laa Exclusion System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.59 | 2019-2025 | Jardiance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $173.98 | 2023-2024 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $172.95 | 2022-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $169.64 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Medtronic, INC. | $155.01 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Biotronik INC. | $153.82 | 2022 | |
| Terumo Medical Corporation | $143.45 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $127.87 | 2023-2025 | Onpattro |
| Heartflow, INC. | $124.39 | 2025 | |
| Lilly USA, LLC | $124.30 | 2023-2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $117.24 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $83.34 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $76.41 | 2025 | Fluency Endovascular Stent Graft |
| Amarin Pharma, INC. | $59.53 | 2019-2021 | |
| Cook Medical LLC | $44.34 | 2019 | |
| Angiodynamics, INC. | $41.23 | 2024 | Auryon Laser System 100-120 Vac |
| Bayer Healthcare Pharmaceuticals INC. | $40.08 | 2025 | |
| Cardiovascular Systems INC. | $38.49 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $35.96 | 2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $34.12 | 2024 | Arcalyst |
| Abiomed | $32.73 | 2020-2024 | Impella |
| Irhythm Technologies, INC. | $25.28 | 2023 | Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.16 | 2019 | |
| Chiesi USA, INC. | $21.84 | 2023 | Kengreal |
| Esperion Therapeutics, INC. | $21.54 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $20.57 | 2025 | Shingrix |
| Edwards Lifesciences Corporation | $17.14 | 2024 | |
| Baxter Healthcare | $12.87 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shishir Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.